ProKidney Corp. (PROK NASDAQ) stock market data APIs
$1.6932
-0.13(-7.7%)
as of May 20, 2026
Try our APIs with
free plan!
ProKidney Corp. Financial Data Overview
Price chart is built with
Anychart
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Prev. Close
1.6932
Open
1.5625
High
1.74
Low
1.5602
52 wk Range
0.54-5.95
Market Cap
468 M
Shares Outstanding
205 M
Revenue
889 K
EPS
-0.14
Beta
1.747
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ProKidney Corp. data using free add-ons & libraries
Get ProKidney Corp. Fundamental Data
ProKidney Corp. Fundamental data includes:
- Net Revenue: 889 K
- EBITDA: -161 919 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-15
- EPS/Forecast: -0.1375
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ProKidney Corp. News
New
ProKidney GAAP EPS of -$0.14 beats by $0.01, revenue of $0.23M beats by $0.03M
* ProKidney press release [https://seekingalpha.com/pr/20517549-prokidney-reports-first-quarter-2026-financial-results-and-business-highlights] (PROK [https://seekingalpha.com/symbol/PROK]): Q1 GAAP...
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago. These figures ar...
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
ProKidney On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 Peer-reviewed results from t...
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.35 per share a year ago. These ...
Get ProKidney Corp. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
